Seeking Alpha

Synageva BioPharma (GEVA -4.3%) slides after its Q4 beats on revenue but comes up short on a per...

Synageva BioPharma (GEVA -4.3%) slides after its Q4 beats on revenue but comes up short on a per share basis. Despite the miss, Piper Jaffray lifts its price target from $53 to $57, citing optimism over upcoming Phase 1/2 data on LAL-D. Wedbush also ups its target to $55 as well.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|